H1N1 Vaccines Market - Regional
Insights
On the basis of geography, H1N1
Vaccines Market is segmented into North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa. North America is expected to lead the
H1N1 vaccines market during the forecast period. This is due to increasing government
initiatives for prevention of H1N1 infection. U.S. which faced major epidemic
in 2009. After this pandemic the U.S. has strengthen the preventive approach to
control H1N1 outbreak by implementing vaccination program. According to
statistics given by Centre for Disease Control
and Prevention in February 2018, during October 1, 2017 and February 3, 2018, clinical laboratories
tested 666,493 specimens for influenza virus, 124,316 (18.7%) of which tested
positive for influenza virus. 84.3% of these tested positive for influenza A.
Furthermore Asia Pacific market
is expected to exhibit the highest CAGR due to high prevalence of swine flu and
increasing awareness about vaccination against H1N1. According to Ministry of
Health and Family Welfare, Government of India, there were 0.1 million cases in
India of H1N1 influenza during 2010 to 2017. Continuous changing nature of the
virus creates challenges to overcome the H1N1 epidemic. For instance, in 2017
new Michigan strain of H1N1 swine flu virus was first identified in India.
Government has played an important role in tackling swine flu by spreading
awareness about H1N1 vaccine The Government of India has published guidelines
for case management of influenza A/H1N1 which classifies influenza patients into
three categories depending on severity. Vaccination was recommended in patient
group which are susceptible to H1N1 fever in future.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2056
H1N1 influenza virus causes viral
disease, commonly known as swine flu, which mostly affects the respiratory system.
Swine flu is characterized by infection from H1N1 strain. Symptoms of H1N1 flu
are fever, cough, sore throat, runny or stuffy nose, watery and red eyes, body
aches, headache, fatigue, and diarrhea. H1N1 spreads through contact with
contaminated air or geographical locations infected with virus. H1N1 infection
may worsen other chronic respiratory conditions such as bronchitis, pneumonia,
COPD, and sometimes even death due to respiratory failure.
H1N1 vaccine is an important
innovation to tackle the H1N1 pandemic since 2009. Initially, the vaccines
developed or available were inactivated monovalent vaccines that could prevent
infection from most of the strains of H1N1. There are two routes of
administration such as intradermal for inactivated vaccine and intranasal for
live attenuated vaccine. Both routes shown efficacy profile and are
bioequivalent against preventing H1N1 infection. Global H1N1 vaccine market has
presence of both multinational pharmaceutical companies and companies from
emerging economies.
H1N1 Vaccines Market - Market
Dynamics
One of the major factor
propelling growth of H1N1 market is increased incidence of disease and episodes
of pandemic worldwide from H1N1 infection. According to World Health
Organization’s (WHO) 2018, factsheet estimates, 290,000 to 650,000 deaths are
reported each year from all types of influenza infection (including Influenza A
i.e. H1N1). Each year there are 3 to 5 million cases of severe illness from
viral influenza infection globally, according to the same source.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/h1n1-vaccines-market-2056
Government initiatives, both
internationally and nationally, to tackle H1N1 pandemic would positively impact
the market growth. Health institution such as World Health Organization (WHO)
have been instrumental in developing vaccines and supporting efficient
distribution of the vaccine. After 2009 pandemic of H1N1 influenza, the U.S.
government initiated US$ 3 billion H1N1 vaccine project under which it
contracted five major companies to develop vaccine for H1N1 influenza. Under
the WHO’s Global Influenza Surveillance and Response System, National Influenza
Centers and WHO Collaborating Centers are continuously monitoring the influenza
viruses circulating in humans and updates the composition of influenza vaccines
twice a year.
Furthermore, rising geriatric
population worldwide would be another impetus for growth of the H1N1 vaccine
market. Global population is crossing the age of 60 at annual rate of 3%
according to 2017 UN report. Increased age, maximizes the risk of various
respiratory tract related diseases and immune deficient diseases, thereby the
risk for infection due to H1N1 virus rises. Awareness amongst patients about
preventive healthcare approaches such as vaccination may lead to higher demand
for H1N1 vaccines during forecast period.
However, seasonal nature of
occurrence of H1N1 flu has led to meagre revenue for many of the key players.
For instance, India-based Serum Institute, which produces intranasal live
vaccine to treat swine flu had to destroy stock of 2 million doses in the year 2011
due to lack of demand. In contrast, if pandemic arises suddenly, supply of
vaccine may be delayed due to slow production of vaccine, which may negatively
affect health of many patients. Due to constant evolving nature of H1N1 virus,
vaccine may prove to be ineffective in some parts of the world, which may deter
the use of vaccines.
H1N1 Vaccines Market -
Competitive Landscape
Key players present in the H1N1
vaccines market are Medimmune, AstraZeneca, GlaxoSmithKline, Novartis, Serum
Institute of India, Abbott Healthcare, Sanofi Pasture, CSL Biotherapeutics,
Sinovac, ID Biomedical Corporation, Cadila Healthcare, and Lupin Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2056
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment